Watchlist

Watchlist
Amgen Inc. (AMGN)
More Positives For Roche, The Core Biotech For The Long Run
Background On November 20, I provided an update on one of my favorite buy-and-hold biotechs, the Swiss giant Roche ( RHHBY ). This focused on recent positive newsflow. Since that article, the company has published two PowerPoint presentations from two different investor conferences, and …
Your Daily Pharma Scoop: Right Time To Buy Regeneron, Eli Lilly Gives Guidance, Bluebird Announces Offering
Content Analysis of coverage: REGN Stocks in the news: LLY, SNY, BLUE Analyst Ratings Insider Sales Insider Purchases Earnings Report Secondary Offerings Earnings Calendar Trade Idea of the Day (for TPT subscribers only) Subscriber Questions & An…
Why Tech Still Looks So Attractive
Introduction - tech on the mend "Tech" is almost always in fashion when the economy is expanding. In the late 1800s, for example, steel production involved high technology. The application of technology to oil extraction allowed the Oil Age to flourish. Today, when we talk about tech, we g…
Amgen declares $1.32 dividend
Amgen (NASDAQ: AMGN ) declares $1.32/share quarterly dividend , 14.8% increase from prior dividend of $1.15. Forward yield 3.0% Payable March 8; for shareholders of record Feb. 15; ex-div Feb. 14. More news on: Amgen Inc., Dividend news,
Amgen Announces 15 Percent Increase In 2018 First Quarter Dividend
THOUSAND OAKS, Calif. , Dec. 12, 2017 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1 .32per share dividend for the first quarter of 2018. The dividend will be paid on March 8, 2018 , to all stockholders of record as of the close …
Amgen to acquire Repros for $0.67 per share
Through a subsidiary, Amgen (NASDAQ: AMGN ) has agreed to acquire Repros Therapeutics (NASDAQ: RPRX ) for $0.67 per share in cash, almost a 43% premium to yesterday's close of $0.47. More news on: Amgen Inc., Repros Therapeutics Inc., Healthcare stocks news, Merger & acquisition news…
Amgen's Kyprolis extends overall survival in blood cancer patients
Amgen (NASDAQ: AMGN ) says a final analysis of late-stage trial data showed that its Kyprolis drug combined with two other drugs - dexamethasone and Celgene's (NASDAQ: CELG ) Revlimid - lowered the risk of death among patients with relapsed or refractory multiple myeloma by 21% and exten…
KYPROLIS® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
THOUSAND OAKS, Calif. , Dec. 11, 2017 /PRNewswire/ --Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addit…
Amgen (AMGN) Presents At 59th American Society Of Hematology Annual Meeting - Slideshow
The following slide deck was published by Amgen Inc. in conjunction with this Read more …
Amgen Foundation Pledges Up To $500,000 In Relief To Victims Of The Southern California Wildfires
THOUSAND OAKS, Calif. , Dec. 11, 2017 /PRNewswire/ --Amgen (NASDAQ:AMGN) today announced that the Amgen Foundation has pledged $500,000 to support victims of the Southern California wildfires. Of this commitment, $200,000 will be directed to the United Way of Ventura County …